- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02358902
Effect of Transcranial Direct Current Stimulation Associated With Aerobic Exercise Training for Patients With Fibromyalgia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The average between the analyzed values was 1.20, with a standard deviation of 0.84, taking into account a type I error of 5%, a type II error of 10% and a power of 80%. From the sample calculation was found an n = 10 for each group. The sample is amplified in order to avoid possible effects of dropout ending with a n = 15 in each group with a total N = 45.
Randomization was performed by a blinded therapist using sealed envelopes for each individual. The subjects will be divided into three intervention groups: tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group, in which will receive active intervention of aerobic exercise training and active tDCS intervention. AE group, which will receive active intervention of aerobic exercise and placebo tDCS. And tDCS group, which will receive placebo AE and active intervention for tDCS.
Participants will be blinded to the intervention groups as well as therapists involved in the evaluation process.
The evaluation methods were carried out one week before the beginning of the intervention (baseline) for all variables. After the first week of intervention (neuromodulatory period) was performed ratings for level of cortical excitability (T1), and after the end of the one month period of intervention for all variables (T2). Follow-up evaluations were conducted one month (T3) and two months (T4) after the end of the intervention period."
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with Fibromyalgia according to the American College of Rheumatology
- Have completed high school
- Age between 18 and 65 years old
Exclusion Criteria:
- Were on medication for pain control for less than two months
- In treatment of depression for less than two months
- Patients with epilepsy, psychiatric disorders or who have any recent episode of neurologic disorders such as idiopathic syncope
- Pregnant women and infants
- Possessing metallic implant in the brain
- In use of illicit drugs
- That were in some kind of physical treatment for less than two months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A
tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group in which will receive active intervention of aerobic exercise training and active tDCS intervention
|
tDCS - DC stimulator, Neurocom, Germany
different types of aerobic exercise
|
|
Experimental: Group B
AE group which will receive active intervention of aerobic exercise and placebo tDCS (tDCS - DC stimulator, Neurocom, Germany)
|
different types of aerobic exercise
only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
|
|
Experimental: Group C
tDCS group which will receive placebo AE and active intervention for tDCS (tDCS - DC stimulator, Neurocom, Germany)
|
tDCS - DC stimulator, Neurocom, Germany
the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Visual Numeric Scale (VNS)
Time Frame: Up to 2 months
|
Pain intensity is measured using a scale from 0 to 10.
A straight 10 cm line is displayed for the subject enumerated from zero to 10, where zero represents no pain and 10 the worst pain possible.
Subjects should mark the number that most represents the symptom of pain at the moment.
Outcome will be measured 24 hours after each intervention session, after 1 month of the end of protocol and 2 months after the end of protocol for evaluation of long term effects.
|
Up to 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Visual Numeric Scale for Anxiety
Time Frame: Up to 2 months
|
This scale has a straight 10 cm enumerated from zero to 10, where zero represents not anxious and 10 the most anxious possible.
Subjects should mark the number that most represents the anxiety level at the moment.
Outcome will be measured 24 hours after each intervention session, after 1 month of the end of protocol and 2 months after the end of protocol for evaluation of long term effects.
|
Up to 2 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pressure Pain Threshold (PPT)
Time Frame: Up to 2 months
|
Using a pressure algometer (Wagner Instruments, USA), pressure is measured in the thenar region of the hand and at the uppermost portion of the anterior tibialis muscle.
Pressure is held until the individual report onset of pain.
At this time the amount of compression performed in kg/force is measured.
Outcome will be measured after one week of intervention, after four weeks of intervention, after 1 month of the end of protocol and 2 months after the end of protocol, for evaluation of long term effects.
|
Up to 2 months
|
|
Change in Diffuse Noxious Inhibitory Control (DNIC-like effects)
Time Frame: Up to 2 months
|
This parameter assesses through intense heterotopic stimulation, the response of endogenous pain modulation.
Subjects emerge the hand in a container with ice-water (10-12˚C) for a period of one minute.
During the last 30 seconds of immersion, the pressure pain threshold is measured in the other hand.
The same procedure is performed for the other side.
Temperature is measured by an immersion thermometer (ALLA BRAZIL 910.0150L).
Outcome will be measured after four weeks of intervention, after 1 month of the end of protocol and 2 months after the end of protocol, for evaluation of long term effects.
|
Up to 2 months
|
|
Change in SF-36 questionnaire of quality of life
Time Frame: Up to 2 months
|
This questionnaire evaluates different aspects in individual life such as: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
Through different questions a score is generated for each subscale where zero represents the worst quality of life and 100 the best quality of life.
Outcome will be measured after four weeks of intervention, after 1 month of the end of protocol and 2 months after the end of protocol, for evaluation of long term effects.
|
Up to 2 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Marcel Simis, MD PhD, Institute of Physical Medicine and Rehabilitation, Clinicas Hospital, Faculty of Medicine, University of Sao Paulo
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08603612.0.0000.5511
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
Selcuk UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...CompletedFibromyalgia (FM)Spain
-
Istanbul Gelisim UniversityBahçeşehir UniversityCompleted
-
Gazi UniversityCompletedFibromyalgia SyndromeTurkey (Türkiye)
-
Ionclinics & Deionic SLHospital Clínico Universitario de ValenciaNot yet recruitingFibromyalgia (FM)Spain
-
Ain Shams UniversityRecruiting
-
University of UtahRecruitingFibromyalgia (FM)United States
-
María Catalina Osuna PérezActive, not recruitingFibromyalgia SyndromeSpain
-
Istanbul UniversityCompletedFibromyalgia | Fibromyalgia Syndrome | Fibromyalgia (FM)Turkey (Türkiye)
Clinical Trials on tDCS
-
Hôpital le VinatierCompletedSchizophrenia | Auditory HallucinationsFrance, Tunisia
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Unknown
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Thorsten RudroffTerminatedMultiple Sclerosis | Neuropathic PainUnited States
-
Nachum Soroker, MDUnknown
-
Bambino Gesù Hospital and Research InstituteCompleted
-
University of MichiganNational Institute of Mental Health (NIMH)Completed
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedMotor Activity | Motor NeuroplasticityUnited States
-
Charite University, Berlin, GermanyCompletedMigraine With Aura | CADASIL | Cerebral Microangiopathy | ICA StenosisGermany
-
New York UniversityRecruiting